Life Extension Magazine®
Sergey A. Dzugan, MD, PhD, was formerly chief of cardiovascular surgery at the Donetsk Regional Medical Center in Donetsk, Ukraine. Dr. Dzugan’s current primary interests are anti-aging, biological therapy for cancer, cholesterol, and hormonal disorders. Migraine, often described as an intense pulsing or throbbing pain in one area of the head, can be a debilitating, even life-threatening disorder. The crippling effects of migraine have been known for thousands of years. In fact, the Ebers papyrus of ancient Egypt, the world’s oldest preserved medical document, contains a long chapter on purported remedies for migraine.1 The specific causes of migraine remain unknown.2 Despite ad-vances in the understanding of the pathophysiology of migraine, effective new treatment options, and repeated initiatives over the years, migraine remains an under-recognized, under-diagnosed, and under-treated health condition in everyday clinical practice. Most patients attempt, without success, to treat their headaches with over-the-counter medications.3,4 In a previously published paper, we described migraine as a consequence of a loss of neurohormonal and metabolic integrity.5 In this case history, we present a patient with long-lasting, severe migraine and a new and very promising approach to correcting this pathology. Background Typically, patient experienced two or three migraine attacks each week. Usually the migraine started in the early afternoon. He often had to go home from work and try to sleep, blocking out all light and sound, and using cold compresses. He rarely suffered an attack at night. For a number of years, CH had simply taken aspirin, Tylenol®, and usually something with caffeine to try to relieve his headaches, without much success. He eventually began to use Imitrex® by injection, a prescription medicine for acute migraine. Although Imitrex® is also available in the form of pills and nasal spray, he had found the pills were not as effective or quick acting, while the nasal spray would drip down his throat and cause him to become nauseous. Usually after taking the injection and lying down for 15 minutes, he could completely abort the migraine. He had also tried pill forms of other medications such as Zomig®, Amerge®, and Maxalt®, but none worked as well as Imitrex®. Occasionally, if CH did not take a shot early enough in the day, he would then have to take an additional one or two doses of Imitrex®. Patient had experienced visual disturbances in about 20% of his migraine attacks and nausea in about 10% of them since he began taking Imitrex® in 1995. He became very adept at recognizing migraine before actually experiencing any head pain, and has not suffered many “full-blown” migraine attacks in recent years. He has always been concerned about the amount of Imitrex® he takes weekly, which is usually two or three doses, but sometimes six or seven. Several years ago, CH also started taking Midrin®, another prescription medication, if he started to get migraine fairly early in the day (three capsules, usually with a Coke for the caffeine). In most instances, however, he was merely postponing the eventual Imitrex® injection. For years now, patient has kept Imitrex® with him at all times (in his desk, briefcase, car, and, depending on where he was or what he was doing, in his pocket). He credits Imitrex® with enabling him to maintain steady employment, become successful in his career, and otherwise live a normal life. CH had a vasectomy in his mid-twenties, but he does not recall a change in the frequency of his migraine following surgery. Five years ago, his doctor in-formed him that his total cholesterol was high. Because of his concerns about the dangers of consuming animal products, patient has followed a vegetarian diet for years. Both his mother and father have suffered from headaches their entire lives. His mother experiences fairly typical migraine, but only a few times a year. His father has almost daily headaches that do not appear to be migraine, and “lives on Excedrin®.” About three and a half years ago, CH had a lower back problem. Magnetic resonance imaging showed that all of the discs in his back seemed to be “thinner” than they should be. Imitrex® was suspected to be the cause of this cartilage deterioration (the Physicians’ Desk Reference entry on Imitrex® alludes to this potential side effect). Patient was terrified by the possibility that he had permanently damaged his health and would suffer for years as a result. His neurologist did not confirm a connection between his use of Imitrex® and the back problem. It was recommended that he continue using Imitrex® because it seemed to work for him. Later, CH had surgery to fix his herniated disk, and he has not had any back problems since the surgery. Over the years, patient has asked many doctors what he could do about his migraine. He has kept countless diaries tracking possible triggers, only to decide that he had a seemingly unending list of potential suspects: stress, computer usage, too little sleep, too much sleep, changes in food or caffeine intake, bright lights, bad smells, wine, cheese, chocolate, and so on. He could not find a common denominator, and was always told to just continue taking Imitrex® since it worked so well for him. During this period, he also began taking an antidepressant (20 mg of Paxil® daily) for symptoms common to depression, including fatigue, lack of motivation, poor memory, and inability to concentrate. Early on, patient “thought” he had noticed a decrease in the frequency of migraine while on Paxil®, and as a result he has taken it religiously for years. CH has tried practically all the currently available supplements for migraine, including feverfew, butterbur extract (Petadolex®), and magnesium. He has likewise used a prescription drug for epilepsy to try to reduce the frequency of migraine, but without success. During these experiments, he continued to use Imitrex®, often fighting with insurance companies to be reimbursed for the injectable form of the drug and the quantity of it required. Patient eventually discovered that he could “half dose” in many cases and still abort his migraine. He conservatively estimates that he has taken over 800 doses of Imitrex® and thousands of Midrin® capsules, and shudders to think of the total costs of these drugs in prescription co-pays and insurance outlays. Based on the $50 cost of an injectable dose, he estimates that he has probably spent at least approximately $40,000 on Imitrex® alone. | ||||
LE Magazine August 2004 | |||||||
Case Report: Migraine Solution By Dr. Sergey A. Dzugan | |||||||
Diagnosis and Treatment The lab report numbers were as follows: total testosterone was 187 ng/dL (standard range is 241-827), pregnenolone was less than 10 ng/dL (standard range is 10-200), and DHEA sulfate was 199 ug/dL (standard range is 280-640). Progesterone, at 1.6 ng/mL, was slightly higher than the maximum standard level (standard range is 0.3-1.2). Estradiol was within the standard range, at 18 pg/dL (standard range is 0-53). Patient’s initial program included:
We discussed with CH the necessity of replacing all three deficient hormones (pregnenolone, DHEA, and testosterone), but he preferred to stay with this initial program without testosterone for a couple of weeks. About a week later, patient began to experience night sweats and his body temperature soared from 95.6 to 102.7 degrees F. His doctor prescribed an antibiotic, and a week or so later the symptoms ceased. Based on his very low testosterone level, we sent him to a urologist for further tests and a testosterone prescription. The urologist ordered a CT scan of his pelvis and head, which apparently showed nothing abnormal. The urologist said he thought CH’s testosterone levels might be low as a result of his vasectomy years ago. He also said he was unaware of any correlation between testosterone levels and migraine incidence. On April 15, 2004, the urologist prescribed TestimTM 1% testosterone gel. Patient began using the gel daily. As of today, CH reports he is completely migraine free. He has also experienced an improvement in sexual function and energy levels, without any negative side effects. Commentary Prophylactic treatment of migraine patients is desirable because the currently prescribed prescription drugs are not always effective in all patients and allow recurrence of headaches in a high percentage of patients, occasionally with severe adverse side effects. It has been previously reported that sex hormones play an important role in the creation and regulation of migraine.10 Significantly low plasma testosterone levels were found in active cluster headache patients.11 CH’s case shows that hormonal restoration is a key element of any program recommended for the management of migraine. Several studies have shown that magnesium and melatonin can provide relief from migraine.12-15 We recommend that both agents be included in treatment programs that aim to eliminate migraine. Because major depression is approximately three times more common in persons with migraine16 and fatigue likewise is common in migraine patients,17 we must stress the importance of the association between hormonal therapy and kava root extract, which may represent an excellent therapeutic tool for treating migraine, particularly for those suffering from anxiety and depression. Kava kava therapy accelerates the resolution of psychological symptoms without diminishing the therapeutic action of hormones. Restoration of natural intestinal flora, from our point of view, is also extremely important in treating migraine, because migraine patients usually take different drugs over the years that change intestinal flora and diminish intestinal absorption. We recommended our program to CH to restore youthful levels of hormones, rebalance the autonomic nervous system (sympathetic and parasympathetic systems), improve the calcium:magnesium ratio, and enhance intestinal absorption. Because CH’s migraines and concomitant symptoms have disappeared, we believe that this case report suggests that similar treatment methodologies may have a wider application in patients with migraine.
| |||||||
References | |||||||
1. Garcia-Albea E. Neurology in the medical papyruses of the pharaohs. Rev Neurol. 1999 Feb 16;28(4):430-3. 2. Edvinsson L. Aspects on the pathophysiology of migraine and cluster headache. Pharmacol Toxicol. 2001 Aug;89(2):65-73. 3. Diamond S, Wenzel R. Practical approaches to migraine management. CNS Drugs. 2002;16(6):385-03. 4. Dowson AJ, Lipscombe S, Sender J, Rees T, Watson D. New guidelines for the management of migraine in primary care. Curr Med Res Opin. 2002;18(7):414-39. 5. Dzugan SA, Smith RA. The simultaneous restoration of neurohormonal and metabolic integrity as a very promising method of migraine management. Bull Urg Rec Med. 2003;(4):622-8. 6. Dzugan SA, Smith RA. Broad spectrum restoration in natural steroid hormones as possible treatment for hypercholesterolemia. Bull Urg Rec Med. 2002;(3):278- 84. 7. Dzugan SA, Smith RA. Hypercholesterolemia treatment: a new hypothesis or just an accident. Med Hypothesis. 2002 Dec;59(6):751-6. 8. Dzugan SA, Smith RA. Hypercholesterolemia treatment: a new hypothesis or just an accident. In: Scientific Conference of Anti-Aging Therapeutics for the Office-Based Physician & Health Practitioner. Fort Lauderdale, FL; 2003:139-155. 9. Ferrari MD, Haan J. The genetics of migraine: implication for treatment approaches. J Neural Transm Suppl. 2002;(63):111-27. 10. Schipper HM. Neurology of sex steroids and oral contraceptives. Neurol Clin. 1986 Nov;4(4):721-51. 11. Kudrow L. Changes of testosterone levels in the cluster headache syndrome. Preliminary study. Minerva Med. 1976 Jun 6;67(28):1850-3. 12. Gagnier JJ. The therapeutic potential of melatonin in migraines and other headache types. Altern Med Rev. 2001 Aug;6(4):383-9. 13. Mauskop A, Altura BM. Role of magnesium in the pathogenesis and treatment of migraines. Clin Neurosci. 1998;5(1):24-7. 14. Li W, Zheng T, Altura BM, Altura BT. Sex steroid hormones exert biphasic effects on cytosolic magnesiumions in cerebral vascular smooth muscle cells: possible relationships to migraine frequency in premenstrual syndromes and stroke incidence. Brain Res Bull. 2001 Jan 1;54(1):83-9. 15. Taubert K. Magnesium in migraine. Results of a multicenter pilot study. Fortschr Med. 1994 Aug 30;112(24):328-30. 16. Kececi H, Dener S, Analan E. Co-morbid- ity of migraine and major depression in the Turkish population. Cephalalgia. 2003 May;23(4):271-5. 17. Peres MF, Zukerman E, Young WB, Silberstein SD. Fatigue in chronic migraine patients. Cephalalgia. 2002 Nov;22(9):720- 4. |